MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

MM-111-02-12-02: A Phase 1 Study of MM-111 in Combination With Herceptin in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Breast Cancer

This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.

Study Overview

• Status: Completed
• Conditions: Breast Neoplasms
• Intervention / Treatment: Drug: MM-111 + Herceptin

Detailed Description

Phase 1: Safety and tolerability of the MM-111 + Herceptin combination will be evaluated and the recommended Phase 2 dose will be determined.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Indiana University (IUPUI)
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • Huntsman Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed advanced breast cancer that is amplified for HER2, based on archived tumor biopsy (IHC 2+ or greater)
• Patients must have histologically or cytologically confirmed advanced breast cancer that is heregulin positive based on fresh tumor tissue biopsy
• The patient's cancer must have recurred, progressed or not responded to standard chemotherapy or other standard treatment. Prior therapies may include but are not limited to Herceptin, Tykerb (lapatinib), anthracyclines, and taxanes
• Patients must be ≥ 18 years of age
• Patients or their legal representatives must be able to understand and sign an informed consent
• Patients may have measurable (per RECIST 1.1) or non-measurable tumor(s) (for Phase 1)
• Patients should have ECOG Performance Score (PS) 0, 1 or 2 (for Phase 1).
• Patients should have a life expectancy of at least 12 weeks
• Patients must have adequate bone marrow reserves
• Patients must have adequate hepatic function
• Patients must have adequate renal function
• Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy.
• Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-111.

Exclusion Criteria:

• Patients who are pregnant or lactating
• Patients with an active infection or with an unexplained fever > 38.5°C (101.3° F) during screening visits or on the first scheduled day of dosing.
• Patients with untreated and/or symptomatic metastatic CNS malignancies.
• Patients with known hypersensitivity to any of the components of MM-111 or who have had hypersensitivity reactions to fully human monoclonal antibodies, including Herceptin.

• Patients who have received other recent antitumor therapy including:

  • Treatment with Herceptin within the 28 days prior to the first scheduled day of dosing with MM-111
  • Investigational therapy administered within the 28 days prior to the first scheduled day of dosing MM-111 (Dosing in less than 28 days' since receiving investigational therapy is acceptable once a time interval equal to at least five half-lives of the investigational agent has passed.)
  • Any standard chemotherapy, Tykerb (lapatinib) or radiation within 14 days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of MM-111
• Patients who have previously received MM-111
• Patients with NYHA Class III or IV congestive heart failure or LVEF < 50%
• Patients with a history of allogeneic transplant
• Patients with known HIV, hepatitis B or C (if patients have previously been treated for hepatitis C and have undetectable viral loads, they can be considered eligible for the trial)
• Patients with any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MM-111 + Herceptin; MM-111 will be combined with Herceptin	Drug: MM-111 + Herceptin; For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV; Other Names: Trastuzumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of Treatment-emergent AE's	2 years

Secondary Outcome Measures

Outcome Measure	Time Frame
To Determine the Recommended Phase 2 Doses of MM-111 + Herceptin in Combination	2 years

Collaborators and Investigators

• Sponsor: Merrimack Pharmaceuticals
• Investigators: Principal Investigator: Michaela Higgins, MD, Massachusetts General Hospital

Study record dates

Study Major Dates

• Study Start: April 1, 2010
• Primary Completion (Actual): July 1, 2013
• Study Completion (Actual): July 1, 2013

Study Registration Dates

• First Submitted: March 30, 2010
• First Submitted That Met QC Criteria: March 31, 2010
• First Posted (Estimate): April 1, 2010

Study Record Updates

• Last Update Posted (Estimate): January 7, 2015
• Last Update Submitted That Met QC Criteria: December 18, 2014
• Last Verified: December 1, 2014

More Information

Terms related to this study

• Keywords: Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Trastuzumab; Herceptin; HER2 Positive Breast Cancer; HER2/HER3; Bispecific Antibody
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Trastuzumab
• Other Study ID Numbers: MM-111-02-12-02